Choy B Y, Chan T M, Lai K N
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong.
Am J Transplant. 2006 Nov;6(11):2535-42. doi: 10.1111/j.1600-6143.2006.01502.x. Epub 2006 Aug 25.
Thirty to fifty percent of kidney transplant recipients have glomerular diseases as the underlying causes of end-stage renal failure. While recurrence of glomerulonephritis is an important cause of late renal allograft failure, the risk factors for recurrence are largely unknown or imprecise and prediction remains difficult. Recurrent disease usually presents with similar manifestations as the native disease. With regard to treatment of recurrent glomerular disease in the renal allograft, plasma exchange may be effective in reducing proteinuria in patients with early recurrence of focal and segmental glomerulosclerosis, but immunosuppressive therapy is generally ineffective in the prevention or treatment of recurrent disease. General supportive measures including strict blood pressure control and inhibition or blockade of the rennin-angiotensin pathway are helpful in retarding the rate of deterioration in renal allograft function. Despite the risk of recurrence, kidney transplantation following primary glomerulonephritides enjoys graft and patient survival rates comparable to other causes of end-stage renal failure. With a few exceptions, living related renal transplantation is not contraindicated in view of the favorable outcome and the donor shortage. This review discusses commonly encountered recurrent glomerulonephritides, with special emphasis on the influence of post-transplant prophylactic immunosuppression and emerging treatments.
30%至50%的肾移植受者患有肾小球疾病,这是终末期肾衰竭的潜在病因。虽然肾小球肾炎复发是肾移植晚期失败的一个重要原因,但复发的危险因素大多未知或不明确,预测仍然困难。复发性疾病通常表现出与原发病相似的症状。关于肾移植中复发性肾小球疾病的治疗,血浆置换可能对早期复发的局灶节段性肾小球硬化患者减少蛋白尿有效,但免疫抑制治疗通常对复发性疾病的预防或治疗无效。包括严格控制血压以及抑制或阻断肾素-血管紧张素途径在内的一般支持措施有助于延缓肾移植功能恶化的速度。尽管存在复发风险,但原发性肾小球肾炎后进行肾移植的移植物和患者生存率与终末期肾衰竭的其他病因相当。除了少数例外情况,鉴于良好的结果和供体短缺,亲属活体肾移植并无禁忌。本综述讨论了常见的复发性肾小球肾炎,特别强调了移植后预防性免疫抑制的影响和新出现的治疗方法。